Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Colombel

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
Urologic Oncology|February 21, 2013
The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinomaEdward N Rampersaud, Tobias Klatte, Geoffrey Bass, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 22, 2007
[Comparison of open and laparoscopic partial nephrectomy: a French multicentre experience]Maxime Crepel, Jean-Christophe Bernhard, Laurent Bellec, et al.
Urology|April 21, 2009
Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristicsClaudio Jeldres, Jean-Jacques Patard, Umberto Capitanio, et al.
European Urology|January 24, 2007
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indicationJean-Jacques Patard, Allan J Pantuck, Maxime Crepel, et al.
Lancet (London, England)|October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.
Urologic Oncology|July 6, 2014
Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoffGéraldine Pignot, Pierre Bigot, Jean-Christophe Bernhard, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Oncotarget|April 28, 2015
Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinomaPrashant Kumar, Sayantani Nandi, Tuan Zea Tan, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
Urologic Oncology|February 21, 2013
The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinomaEdward N Rampersaud, Tobias Klatte, Geoffrey Bass, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 22, 2007
[Comparison of open and laparoscopic partial nephrectomy: a French multicentre experience]Maxime Crepel, Jean-Christophe Bernhard, Laurent Bellec, et al.
Urology|April 21, 2009
Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristicsClaudio Jeldres, Jean-Jacques Patard, Umberto Capitanio, et al.
European Urology|January 24, 2007
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indicationJean-Jacques Patard, Allan J Pantuck, Maxime Crepel, et al.
Lancet (London, England)|October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
European Urology Oncology|January 4, 2026
Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate CancerFrançois Rozet, Alain Ruffion, Pablo Lemercier, et al.
Urologic Oncology|July 6, 2014
Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoffGéraldine Pignot, Pierre Bigot, Jean-Christophe Bernhard, et al.
World Journal of Urology|July 22, 2023
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trialThierry Lebret, Xavier Paoletti, Geraldine Pignot, et al.
Oncotarget|April 28, 2015
Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinomaPrashant Kumar, Sayantani Nandi, Tuan Zea Tan, et al.
Pageof 12